TAF isn't superior anything. TAF is simply sort-of fixing Viread's renal problem. They created a problem and now they are sort-of fixing it right before their patent runs out. I call it job security.
But it isn't generics and insurers that are the biggest commercial threat, it's Triumeq.
Market Data 
Markets 
AI
